NSE filing, NSE: HSCL. Summary written from the filing by ALFA Finder's alert engine.
Himadri Speciality Chemical Ltd: key numbers
- Share price
- ₹530.55
- Market cap
- ₹26,770 Cr
- Revenue (annual)
- ₹4,661 Cr
- Net profit (annual)
- ₹751.3 Cr
- P/E (TTM)
- 31.3×Sector 34.1×
- Promoter holding
- 52.49%-0.01% QoQ
- FII holding
- 7.33%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Himadri Speciality Chemical Ltd
All →Himadri Speciality Chemical Other Announcement
Himadri Speciality Chemical's members approved an alteration of its Memorandum of Association and adoption of a new MOA under the Companies Act, 2013. The approval was by special resolution through postal ballot on October 27, 2026.
Himadri Speciality Chemical Annual General Meeting
Himadri Speciality Chemical announced postal ballot results approving a special resolution to alter and adopt a new Memorandum of Association. Remote e-voting concluded 27 October 2026 with the requisite majority.
Himadri Speciality Chemical Earnings Call Transcript: Key Takeaways
Himadri delivered massive 58% revenue growth while maintaining steady margins despite high freight costs.
Himadri Speciality Chemical Investor Presentation: Key Takeaways
Himadri reported strong Q2 FY27 performance with revenue at ₹1,691 Cr and PAT at ₹231 Cr, driven by high-value product transitions and expansion into battery materials.
Himadri Speciality Chemical Results Update
Himadri Speciality Chemical reported consolidated H1FY27 revenue of ₹3,123 Cr and PAT of ₹460 Cr, reflecting growth across its specialty chemicals and battery material portfolios.
Himadri Speciality Chemical Q2 FY27 Results: Net Profit ₹231.3 Cr, Up 31.3% YoY
Himadri Speciality Chemical Ltd reported revenue from operations of ₹1,691 Cr (+57.9% YoY) and net profit of ₹231.3 Cr (+31.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹231.3 Cr · +31.3% YoY
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr